Seller record · Telehealth service

Framework

By Paul Harris, Standards EditorRecorded September 2026 · Standard v1.1 · How checks are performed

Fails 3 of 8 criteria. S3, pharmacy identification: No filling pharmacy is named. The answer to which pharmacies it works with says only state-licensed compounding pharmacies regulated by state boards of pharmacy. 2 more criteria also fail; see the table below.

At a glance

FrameworkTelehealth service

5/8criteria passed

Price: GLP-1 treatment from $25 a week, no membership fee
Sells: compounded semaglutide, compounded tirzepatide
FDA letters: None on file

Visit Framework See all eight dispositions

Telehealth service. Passes 5 of 8 criteria. Recorded against Standard v1.1.

A telehealth platform based in Puerto Rico selling compounded semaglutide and tirzepatide on a subscription, with prescribing by physicians licensed in each state and dietitian support. Care starts with a health intake questionnaire, and no pharmacy is named.

Operating entity Framework LLC

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	PASS	Framework's terms of service page; Framework's website
S2	Prescription gating	PASS	Framework's terms of service page
S3	Pharmacy identification	FAIL	Framework's website; Framework's terms of service page
S4	Compounding disclosure	FAIL	Framework's website
S5	Analytical documentation	FAIL	Framework's website; Framework's terms of service page
S6	Business address	PASS	Framework's terms of service page; Framework's privacy policy; Framework's HIPAA notice
S7	Price disclosure	PASS	Framework's website; Framework's GLP page
S8	Enforcement status	PASS	FDA warning-letter index

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSThe terms say a physician licensed in the patient's state reviews each intake and decides whether treatment is medically appropriate, and that no prescription is guaranteed.Source: Framework's terms of service page; Framework's website.

S2PASSThe terms say an account is created by completing a health intake questionnaire, that a physician then reviews the intake, and that an order is declined and the payment refunded if no prescription is issued.Source: Framework's terms of service page.

S3FAILNo filling pharmacy is named. The answer to which pharmacies it works with says only state-licensed compounding pharmacies regulated by state boards of pharmacy.Source: Framework's website; Framework's terms of service page.

S4FAILThe answer to whether GLP-1s are safe says that GLP-1 medications are FDA-approved, on a site that sells only compounded GLP-1 medications, although the footer says the compounded products are not approved by the FDA.Source: Framework's website.

S5FAILNo certificate of analysis or lot document is published on the home page, in the answers, the terms or the privacy policy.Source: Framework's website; Framework's terms of service page.

S6PASS151 C. de San Francisco, San Juan, Puerto Rico 00646, printed in the terms, in the privacy policy for Framework LLC and in the HIPAA notice. The terms name California law.Source: Framework's terms of service page; Framework's privacy policy; Framework's HIPAA notice.

S7PASSGLP-1 treatment for as low as $25 a week with no membership fee on the home page, while another of its own landing pages prints as low as $19 a week. No price is printed for either medication or for any dose.Source: Framework's website; Framework's GLP page.

S8PASSNo FDA warning letter names Framework or Framework LLC, and no action has halted the business.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide.

Other sellers of the same products

Who sells semaglutide Who sells tirzepatide

Visit Framework

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.